Gossamer Bio is trading at $9.96, down 7.61%, amid biotech-sector pressure.
- No new company-specific announcement or direct catalyst was identified for the October 7 decline; the company’s latest prominent news was its September 23 FDA application submission.
- The sector context showed XBI down 2.50%, as elevated Treasury yields and Fed uncertainty weighed on rate-sensitive biotech stocks.
- The broader market was also weaker, but the sector decline appears more relevant.